TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Milenković, Marija
AU  - Basarić, Dusica
AU  - Tomić, Branko
AU  - Marković, Olivera
AU  - Zdravković, Marija
AU  - Ignjatović, Vera
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1516
AB  - Background: Coagulation dysfunction represents a serious complication in patients during the COVID-19 infec-tion, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease. However, there is very little data on association of congenital thrombophilia and thrombotic events in the setting of COVID-19. Our study aimed to evaluate the risk of COVID-19 associated thrombosis in patients with congenital thrombophilia. Methods: This prospective, case-control study included patients with confirmed COVID-19 infection, followed 6 months post-confirmation. The final outcome was a symptomatic thrombotic event. In total, 90 COVID-19 pa-tients, 30 with known congenital thrombophilia and 60 patients without thrombophilia within the period July 2020-November 2021, were included in the study. Evaluation of hemostatic parameters including FVIII activity and D-dimer was performed for all patients at 1 month, 3 months and 6 months post-COVID-19 diagnosis. Results: Symptomatic thrombotic events were observed in 7 out of 30 (23 %) COVID-19 patients with throm-bophilia, and 12 out of 60 (20 %) without thrombophilia, P = 0.715. In addition, the two patient groups had comparable localization of thrombotic events, time to thrombotic event, effect of antithrombotic treatment and changes in FVIII activity, while D-dimer level were significantly increased in patients without thrombophilia. Conclusion: Our findings suggest that patients with congenital thrombophilia, irrespective of their age, a mild clinical picture and absence of comorbidities, should receive anticoagulant prophylaxis, adjusted based on the specific genetic defect.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection
EP  - 156
SP  - 151
VL  - 218
DO  - 10.1016/j.thromres.2022.08.020
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Milenković, Marija and Basarić, Dusica and Tomić, Branko and Marković, Olivera and Zdravković, Marija and Ignjatović, Vera",
year = "2022",
abstract = "Background: Coagulation dysfunction represents a serious complication in patients during the COVID-19 infec-tion, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease. However, there is very little data on association of congenital thrombophilia and thrombotic events in the setting of COVID-19. Our study aimed to evaluate the risk of COVID-19 associated thrombosis in patients with congenital thrombophilia. Methods: This prospective, case-control study included patients with confirmed COVID-19 infection, followed 6 months post-confirmation. The final outcome was a symptomatic thrombotic event. In total, 90 COVID-19 pa-tients, 30 with known congenital thrombophilia and 60 patients without thrombophilia within the period July 2020-November 2021, were included in the study. Evaluation of hemostatic parameters including FVIII activity and D-dimer was performed for all patients at 1 month, 3 months and 6 months post-COVID-19 diagnosis. Results: Symptomatic thrombotic events were observed in 7 out of 30 (23 %) COVID-19 patients with throm-bophilia, and 12 out of 60 (20 %) without thrombophilia, P = 0.715. In addition, the two patient groups had comparable localization of thrombotic events, time to thrombotic event, effect of antithrombotic treatment and changes in FVIII activity, while D-dimer level were significantly increased in patients without thrombophilia. Conclusion: Our findings suggest that patients with congenital thrombophilia, irrespective of their age, a mild clinical picture and absence of comorbidities, should receive anticoagulant prophylaxis, adjusted based on the specific genetic defect.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection",
pages = "156-151",
volume = "218",
doi = "10.1016/j.thromres.2022.08.020"
}

Kovač, M., Mitić, G., Milenković, M., Basarić, D., Tomić, B., Marković, O., Zdravković, M.,& Ignjatović, V.. (2022). Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 218, 151-156.
https://doi.org/10.1016/j.thromres.2022.08.020

Kovač M, Mitić G, Milenković M, Basarić D, Tomić B, Marković O, Zdravković M, Ignjatović V. Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection. in Thrombosis Research. 2022;218:151-156.
doi:10.1016/j.thromres.2022.08.020 .

Kovač, Mirjana, Mitić, Gorana, Milenković, Marija, Basarić, Dusica, Tomić, Branko, Marković, Olivera, Zdravković, Marija, Ignjatović, Vera, "Thrombosis risk assessment in patients with congenital thrombophilia during COVID-19 infection" in Thrombosis Research, 218 (2022):151-156,
https://doi.org/10.1016/j.thromres.2022.08.020 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Miković, Zeljko
AU  - Mandić, Vesna
AU  - Miljić, Predrag
AU  - Mitrović, Mirjana
AU  - Tomić, Branko
AU  - Bereczky, Zsuzsanna
PY  - 2019
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1287
AB  - Background: Inherited antithrombin (AT) deficiency is a rare autosomal dominant disorder, caused by mutations in the SERPINC1 gene. The most common clinical presentation in AT deficient patients includes venous thrombosis and pulmonary embolism, while the association of AT deficiency and its effect on the development of pregnancy complications has been less studied. The aim of our research was to evaluate the effect of AT deficiency types, determined by genotyping, on pregnancy outcomes. Methods: A retrospective cohort study included 28 women with AT deficiency, and their 64 pregnancies were analyzed. Results: With regard to live birth rate, a significant difference was observed among women who were carriers of different SERPINC1 mutations, as the rate varied from 100% in cases of type I to the extremely low rate of 8% for women with type II HBS (AT Budapest 3) in the homozygous variant, P=0.0005. All pregnancies from the type I group, even untreated ones, resulted in live births. In women with AT Budapest 3 in homozygous variant the overall live birth rate increased to 28.5% in the treated pregnancies. In this group the highest incidence of fetal death was observed of 62%; repeated fetal losses in 30%; fetal growth restriction in 22% and placental abruption in 7% of all pregnancies. Conclusion: Our study results indicate a difference between type I and type II AT deficiency. The risk of pregnancy related VTE was equally present in both groups, except for AT Budapest 3 in the heterozygous variant, while adverse pregnancy outcomes were strictly related to type II, especially AT Budapest 3 in the homozygous variant.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications
EP  - 19
SP  - 12
VL  - 173
DO  - 10.1016/j.thromres.2018.11.006
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Miković, Zeljko and Mandić, Vesna and Miljić, Predrag and Mitrović, Mirjana and Tomić, Branko and Bereczky, Zsuzsanna",
year = "2019",
abstract = "Background: Inherited antithrombin (AT) deficiency is a rare autosomal dominant disorder, caused by mutations in the SERPINC1 gene. The most common clinical presentation in AT deficient patients includes venous thrombosis and pulmonary embolism, while the association of AT deficiency and its effect on the development of pregnancy complications has been less studied. The aim of our research was to evaluate the effect of AT deficiency types, determined by genotyping, on pregnancy outcomes. Methods: A retrospective cohort study included 28 women with AT deficiency, and their 64 pregnancies were analyzed. Results: With regard to live birth rate, a significant difference was observed among women who were carriers of different SERPINC1 mutations, as the rate varied from 100% in cases of type I to the extremely low rate of 8% for women with type II HBS (AT Budapest 3) in the homozygous variant, P=0.0005. All pregnancies from the type I group, even untreated ones, resulted in live births. In women with AT Budapest 3 in homozygous variant the overall live birth rate increased to 28.5% in the treated pregnancies. In this group the highest incidence of fetal death was observed of 62%; repeated fetal losses in 30%; fetal growth restriction in 22% and placental abruption in 7% of all pregnancies. Conclusion: Our study results indicate a difference between type I and type II AT deficiency. The risk of pregnancy related VTE was equally present in both groups, except for AT Budapest 3 in the heterozygous variant, while adverse pregnancy outcomes were strictly related to type II, especially AT Budapest 3 in the homozygous variant.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications",
pages = "19-12",
volume = "173",
doi = "10.1016/j.thromres.2018.11.006"
}

Kovač, M., Mitić, G., Miković, Z., Mandić, V., Miljić, P., Mitrović, M., Tomić, B.,& Bereczky, Z.. (2019). The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 173, 12-19.
https://doi.org/10.1016/j.thromres.2018.11.006

Kovač M, Mitić G, Miković Z, Mandić V, Miljić P, Mitrović M, Tomić B, Bereczky Z. The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications. in Thrombosis Research. 2019;173:12-19.
doi:10.1016/j.thromres.2018.11.006 .

Kovač, Mirjana, Mitić, Gorana, Miković, Zeljko, Mandić, Vesna, Miljić, Predrag, Mitrović, Mirjana, Tomić, Branko, Bereczky, Zsuzsanna, "The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications" in Thrombosis Research, 173 (2019):12-19,
https://doi.org/10.1016/j.thromres.2018.11.006 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Đilas, Iva
AU  - Kuzmanović, Milos
AU  - Serbić, Olivera
AU  - Leković, Danijela
AU  - Tomić, Branko
AU  - Bereczky, Zsuzsanna
PY  - 2019
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1208
AB  - Inherited antithrombin (AT) deficiency is a rare autosomal dominant disorder, caused by mutations in the AT gene (SERPINC1). Considering that the genotype phenotype relationship in AT deficiency patients remains unclear, especially in pediatric patients, the aim of our study was to evaluate genotype phenotype correlation in a Serbian pediatric population. A retrospective cohort study included 19 children younger than 18 years, from 15 Serbian families, with newly diagnosed AT deficiency. In 21% of the recruited families, mutations affecting exon 4, 5, and 6 of the SERPINC1 gene that causes type I AT deficiency were detected. In the remaining families, the mutation in exon 2 causing type II HBS (AT Budapest 3) was found. Thrombosis events were observed in 1 (33%) of those with type I, 11 (85%) of those with AT Budapest 3 in the homozygous respectively, and 1(33%) in the heterozygous form. Recurrent thrombosis was observed only in AT Budapest 3 in the homozygous form, in 27% during initial treatment of the first thrombotic event. Abdominal venous thrombosis and arterial ischemic stroke, observed in almost half of the children from the group with AT Budapest 3 in the homozygous form, were unprovoked in all cases. Conclusion: Type II HBS (AT Budapest 3) in the homozygous form is a strong risk factor for arterial and venous thrombosis in pediatric patients.What is Known:center dot Inherited AT deficiency is a rare autosomal dominant disorder, caused by mutations in the SERPINC1gene.center dot The genotype phenotype correlation in AT deficiency patients remains unclear, especially in pediatric patients.What is New:center dot The genetic results for our paediatric population predominantly showed the presence of a single specific mutation in exon 2, that causes type II HBS deficiency (AT Budapest 3).center dot In this group thrombosis mostly occurred as unprovoked, in almost half of them as abdominal thrombosis or stroke with high incidence of recurrent thrombosis, in 27% during initial treatment.
PB  - Springer, New York
T2  - European Journal of Pediatrics
T1  - Genotype phenotype correlation in a pediatric population with antithrombin deficiency
EP  - 1478
IS  - 10
SP  - 1471
VL  - 178
DO  - 10.1007/s00431-019-03433-5
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Đilas, Iva and Kuzmanović, Milos and Serbić, Olivera and Leković, Danijela and Tomić, Branko and Bereczky, Zsuzsanna",
year = "2019",
abstract = "Inherited antithrombin (AT) deficiency is a rare autosomal dominant disorder, caused by mutations in the AT gene (SERPINC1). Considering that the genotype phenotype relationship in AT deficiency patients remains unclear, especially in pediatric patients, the aim of our study was to evaluate genotype phenotype correlation in a Serbian pediatric population. A retrospective cohort study included 19 children younger than 18 years, from 15 Serbian families, with newly diagnosed AT deficiency. In 21% of the recruited families, mutations affecting exon 4, 5, and 6 of the SERPINC1 gene that causes type I AT deficiency were detected. In the remaining families, the mutation in exon 2 causing type II HBS (AT Budapest 3) was found. Thrombosis events were observed in 1 (33%) of those with type I, 11 (85%) of those with AT Budapest 3 in the homozygous respectively, and 1(33%) in the heterozygous form. Recurrent thrombosis was observed only in AT Budapest 3 in the homozygous form, in 27% during initial treatment of the first thrombotic event. Abdominal venous thrombosis and arterial ischemic stroke, observed in almost half of the children from the group with AT Budapest 3 in the homozygous form, were unprovoked in all cases. Conclusion: Type II HBS (AT Budapest 3) in the homozygous form is a strong risk factor for arterial and venous thrombosis in pediatric patients.What is Known:center dot Inherited AT deficiency is a rare autosomal dominant disorder, caused by mutations in the SERPINC1gene.center dot The genotype phenotype correlation in AT deficiency patients remains unclear, especially in pediatric patients.What is New:center dot The genetic results for our paediatric population predominantly showed the presence of a single specific mutation in exon 2, that causes type II HBS deficiency (AT Budapest 3).center dot In this group thrombosis mostly occurred as unprovoked, in almost half of them as abdominal thrombosis or stroke with high incidence of recurrent thrombosis, in 27% during initial treatment.",
publisher = "Springer, New York",
journal = "European Journal of Pediatrics",
title = "Genotype phenotype correlation in a pediatric population with antithrombin deficiency",
pages = "1478-1471",
number = "10",
volume = "178",
doi = "10.1007/s00431-019-03433-5"
}

Kovač, M., Mitić, G., Đilas, I., Kuzmanović, M., Serbić, O., Leković, D., Tomić, B.,& Bereczky, Z.. (2019). Genotype phenotype correlation in a pediatric population with antithrombin deficiency. in European Journal of Pediatrics
Springer, New York., 178(10), 1471-1478.
https://doi.org/10.1007/s00431-019-03433-5

Kovač M, Mitić G, Đilas I, Kuzmanović M, Serbić O, Leković D, Tomić B, Bereczky Z. Genotype phenotype correlation in a pediatric population with antithrombin deficiency. in European Journal of Pediatrics. 2019;178(10):1471-1478.
doi:10.1007/s00431-019-03433-5 .

Kovač, Mirjana, Mitić, Gorana, Đilas, Iva, Kuzmanović, Milos, Serbić, Olivera, Leković, Danijela, Tomić, Branko, Bereczky, Zsuzsanna, "Genotype phenotype correlation in a pediatric population with antithrombin deficiency" in European Journal of Pediatrics, 178, no. 10 (2019):1471-1478,
https://doi.org/10.1007/s00431-019-03433-5 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Lalić-Cosić, Sanja
AU  - Đorđević, Valentina
AU  - Tomić, Branko
AU  - Muszbek, Laszlo
AU  - Bereczky, Zsuzsanna
PY  - 2018
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1108
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Evaluation of endogenous thrombin potential among patients with antithrombin deficiency
EP  - 53
SP  - 50
VL  - 166
DO  - 10.1016/j.thromres.2018.04.004
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Lalić-Cosić, Sanja and Đorđević, Valentina and Tomić, Branko and Muszbek, Laszlo and Bereczky, Zsuzsanna",
year = "2018",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Evaluation of endogenous thrombin potential among patients with antithrombin deficiency",
pages = "53-50",
volume = "166",
doi = "10.1016/j.thromres.2018.04.004"
}

Kovač, M., Mitić, G., Lalić-Cosić, S., Đorđević, V., Tomić, B., Muszbek, L.,& Bereczky, Z.. (2018). Evaluation of endogenous thrombin potential among patients with antithrombin deficiency. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 166, 50-53.
https://doi.org/10.1016/j.thromres.2018.04.004

Kovač M, Mitić G, Lalić-Cosić S, Đorđević V, Tomić B, Muszbek L, Bereczky Z. Evaluation of endogenous thrombin potential among patients with antithrombin deficiency. in Thrombosis Research. 2018;166:50-53.
doi:10.1016/j.thromres.2018.04.004 .

Kovač, Mirjana, Mitić, Gorana, Lalić-Cosić, Sanja, Đorđević, Valentina, Tomić, Branko, Muszbek, Laszlo, Bereczky, Zsuzsanna, "Evaluation of endogenous thrombin potential among patients with antithrombin deficiency" in Thrombosis Research, 166 (2018):50-53,
https://doi.org/10.1016/j.thromres.2018.04.004 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Jesić, Milos
AU  - Đorđević, Valentina
AU  - Muszbek, Laszlo
AU  - Bereczky, Zsuzsanna
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1072
AB  - The overall incidence of thromboembolic events in the neonatal period is 5 per 100 000 births, wherein more than 40% of all such manifestations are symptomatic renal vein thromboses. We describe the case of a newborn female who developed extensive thrombosis, which filled the inferior vena cava and renal vein and was diagnosed in the first weeks of life. A homozygous type II heparin-binding site antithrombin deficiency (c.391C gt T, p.Leu131Phe) was detected in the background. Despite the timely diagnosis and appropriate treatment, clinical signs of renal insufficiency, because of left kidney atrophy and arterial hypertension, were observed. Our case demonstrates the seriousness of the consequences arising after early onset of venous thrombosis caused by homozygous type II heparin-binding site antithrombin deficiency. In addition to prompt diagnosis, of huge importance is the determination of inherited thrombophilia, as it significantly affects therapeutic treatment and indicates that long-term follow-up is mandatory.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Blood Coagulation & Fibrinolysis
T1  - Early onset of abdominal venous thrombosis in a newborn with homozygous type II heparin-binding site antithrombin deficiency
EP  - 266
IS  - 3
SP  - 264
VL  - 28
DO  - 10.1097/MBC.0000000000000570
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Jesić, Milos and Đorđević, Valentina and Muszbek, Laszlo and Bereczky, Zsuzsanna",
year = "2017",
abstract = "The overall incidence of thromboembolic events in the neonatal period is 5 per 100 000 births, wherein more than 40% of all such manifestations are symptomatic renal vein thromboses. We describe the case of a newborn female who developed extensive thrombosis, which filled the inferior vena cava and renal vein and was diagnosed in the first weeks of life. A homozygous type II heparin-binding site antithrombin deficiency (c.391C gt T, p.Leu131Phe) was detected in the background. Despite the timely diagnosis and appropriate treatment, clinical signs of renal insufficiency, because of left kidney atrophy and arterial hypertension, were observed. Our case demonstrates the seriousness of the consequences arising after early onset of venous thrombosis caused by homozygous type II heparin-binding site antithrombin deficiency. In addition to prompt diagnosis, of huge importance is the determination of inherited thrombophilia, as it significantly affects therapeutic treatment and indicates that long-term follow-up is mandatory.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Blood Coagulation & Fibrinolysis",
title = "Early onset of abdominal venous thrombosis in a newborn with homozygous type II heparin-binding site antithrombin deficiency",
pages = "266-264",
number = "3",
volume = "28",
doi = "10.1097/MBC.0000000000000570"
}

Kovač, M., Mitić, G., Jesić, M., Đorđević, V., Muszbek, L.,& Bereczky, Z.. (2017). Early onset of abdominal venous thrombosis in a newborn with homozygous type II heparin-binding site antithrombin deficiency. in Blood Coagulation & Fibrinolysis
Lippincott Williams & Wilkins, Philadelphia., 28(3), 264-266.
https://doi.org/10.1097/MBC.0000000000000570

Kovač M, Mitić G, Jesić M, Đorđević V, Muszbek L, Bereczky Z. Early onset of abdominal venous thrombosis in a newborn with homozygous type II heparin-binding site antithrombin deficiency. in Blood Coagulation & Fibrinolysis. 2017;28(3):264-266.
doi:10.1097/MBC.0000000000000570 .

Kovač, Mirjana, Mitić, Gorana, Jesić, Milos, Đorđević, Valentina, Muszbek, Laszlo, Bereczky, Zsuzsanna, "Early onset of abdominal venous thrombosis in a newborn with homozygous type II heparin-binding site antithrombin deficiency" in Blood Coagulation & Fibrinolysis, 28, no. 3 (2017):264-266,
https://doi.org/10.1097/MBC.0000000000000570 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Miković, Zeljko
AU  - Mandić, Vesna
AU  - Đorđević, Valentina
AU  - Muszbek, Laszlo
AU  - Bereczky, Zsuzsanna
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/990
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency
EP  - 113
SP  - 111
VL  - 139
DO  - 10.1016/j.thromres.2016.01.018
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Miković, Zeljko and Mandić, Vesna and Đorđević, Valentina and Muszbek, Laszlo and Bereczky, Zsuzsanna",
year = "2016",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency",
pages = "113-111",
volume = "139",
doi = "10.1016/j.thromres.2016.01.018"
}

Kovač, M., Mitić, G., Miković, Z., Mandić, V., Đorđević, V., Muszbek, L.,& Bereczky, Z.. (2016). Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 139, 111-113.
https://doi.org/10.1016/j.thromres.2016.01.018

Kovač M, Mitić G, Miković Z, Mandić V, Đorđević V, Muszbek L, Bereczky Z. Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency. in Thrombosis Research. 2016;139:111-113.
doi:10.1016/j.thromres.2016.01.018 .

Kovač, Mirjana, Mitić, Gorana, Miković, Zeljko, Mandić, Vesna, Đorđević, Valentina, Muszbek, Laszlo, Bereczky, Zsuzsanna, "Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency" in Thrombosis Research, 139 (2016):111-113,
https://doi.org/10.1016/j.thromres.2016.01.018 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Miković, Zeljko
AU  - Mitić, Gorana
AU  - Đorđević, Valentina
AU  - Mandić, Vesna
AU  - Rakićević, Ljiljana
AU  - Radojković, Dragica
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/783
AB  - The study was conducted to evaluate the effect of anticoagulant therapy in women with thrombophilia and to detect the possible differences among carriers of mutations (factor V [FV] Leiden and FIIG20210) and those with natural anticoagulant deficiency. The 4-year prospective investigation included 85 pregnant women, with a history of recurrent fetal loss (RFL). They were treated with prophylactic doses of low-molecular-weight heparin (nadroparin) starting from 6 to 8 weeks of gestation. Pregnancy outcomes were evaluated based on the thrombophilia type. Carriers of thrombophilic mutations had a live birth rate of 93%, compared to 41.6% for women with natural anticoagulant deficiencies. Significant differences between the groups were also observed for intrauterine fetal death, intrauterine growth restriction, and postpartum thrombosis. The optimal therapy for women with natural anticoagulant deficiency and RFL remains unclear and future prospective study with a large number of patients is required to determine the best treatment for these severe thrombophilic conditions.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Clinical and Applied Thrombosis-Hemostasis
T1  - Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?
EP  - 189
IS  - 2
SP  - 184
VL  - 20
DO  - 10.1177/1076029612468940
ER  - 

@article{
author = "Kovač, Mirjana and Miković, Zeljko and Mitić, Gorana and Đorđević, Valentina and Mandić, Vesna and Rakićević, Ljiljana and Radojković, Dragica",
year = "2014",
abstract = "The study was conducted to evaluate the effect of anticoagulant therapy in women with thrombophilia and to detect the possible differences among carriers of mutations (factor V [FV] Leiden and FIIG20210) and those with natural anticoagulant deficiency. The 4-year prospective investigation included 85 pregnant women, with a history of recurrent fetal loss (RFL). They were treated with prophylactic doses of low-molecular-weight heparin (nadroparin) starting from 6 to 8 weeks of gestation. Pregnancy outcomes were evaluated based on the thrombophilia type. Carriers of thrombophilic mutations had a live birth rate of 93%, compared to 41.6% for women with natural anticoagulant deficiencies. Significant differences between the groups were also observed for intrauterine fetal death, intrauterine growth restriction, and postpartum thrombosis. The optimal therapy for women with natural anticoagulant deficiency and RFL remains unclear and future prospective study with a large number of patients is required to determine the best treatment for these severe thrombophilic conditions.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Clinical and Applied Thrombosis-Hemostasis",
title = "Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?",
pages = "189-184",
number = "2",
volume = "20",
doi = "10.1177/1076029612468940"
}

Kovač, M., Miković, Z., Mitić, G., Đorđević, V., Mandić, V., Rakićević, L.,& Radojković, D.. (2014). Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?. in Clinical and Applied Thrombosis-Hemostasis
Sage Publications Inc, Thousand Oaks., 20(2), 184-189.
https://doi.org/10.1177/1076029612468940

Kovač M, Miković Z, Mitić G, Đorđević V, Mandić V, Rakićević L, Radojković D. Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?. in Clinical and Applied Thrombosis-Hemostasis. 2014;20(2):184-189.
doi:10.1177/1076029612468940 .

Kovač, Mirjana, Miković, Zeljko, Mitić, Gorana, Đorđević, Valentina, Mandić, Vesna, Rakićević, Ljiljana, Radojković, Dragica, "Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?" in Clinical and Applied Thrombosis-Hemostasis, 20, no. 2 (2014):184-189,
https://doi.org/10.1177/1076029612468940 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Miković, Željko
AU  - Mandić, Vesna
AU  - Radojković, Dragica
AU  - Đorđević, Valentina
AU  - Mitić, Gorana
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/728
AB  - Uvod. Venski tromboembolizam je multifaktorijalna bolest koja nastaje u interakciji genetskog i stečenog faktora rizika. Nakon bolesti koronarnih krvnih sudova i moždanog udara, najčešći je razlog kardiovaskularne smrti ili onesposobljenosti. Materijal i metode. Sa ciljem da se utvrde kliničke krakteristike prvog venskog tromboembolizma, u studiju je uključeno 447 žena mlađih od 45 i 174 žene starije od 45 godina, koje su testirane na prisustvo trombofilije u periodu 1998-2012. godine. Rezultati. Proksimalna duboka venska tromboza češće je zastupljena kod mladih žena, dok je distalna učestalija u grupi starijih. Najčešći faktor rizika za trombozu, koji je utvrđen kod 49,8% mladih žena je trudnoća i stanje posle porođaja, dok se kod 25,2% tromboza razvila bez jasno prepoznatljivog faktora rizika. U grupi starijih žena, tromboza nastaje kod 38,5% bez faktora rizika, dok je malignitet kao najznačajniji faktor rizika utvrđen kod 23%. Prisustvo trombofilije zabeleženo je kod 48,7% mladih, odnosno kod 28,7% starijih žena, p  lt  0,001. Razlika se beleži i u odnosu na ponavljane venske tromboze koje su zabeležene kod 26,3% mladih, odnosno kod 17,8% starijih žena, p = 0,03. Zaključak. Kod mladih žena se razvijaju klinički teže venske tromboze nego kod starijih. Urođeni faktor rizika otkriven je kod skoro polovine mladih ispitanica, odnosno kod svake četvrte starije žene. Sa izuzetkom faktora V Leiden mutacije ostali tipovi urođene trombofilije su gotovo zanemarljivi u grupi starijih žena. Stoga je testiranje na prisustvo trombofilije u slučaju prve tromboze, u potpunosti opravdano samo kod mlađih žena.
AB  - Introduction. Venous thromboembolism is a multifactorial disease defined by multiple interactions between genetic and acquired risk factors. After coronary heart disease and stroke, venous thromboembolism is the most common cause of cardiovascular death and disability. Material and Methods. In order to investigate the clinical characteristics of first venous thromboembolism, 447 women younger than 45 and 174 over 45 years of age with confirmed venous thromboembolism, who had been tested for the presence of thrombophilia in the period 1998-2012, were included in the study. Results. Proximal deep vein thrombosis occurred most often among young women, while distal deep vein thrombosis was the most frequent in the older group. The most common reported risk for venous thromboembolism observed in 49.8% of the young women was pregnancy and puerperium, while 25.2% of them developed venous thromboembolism without any obvious cause. Among women over the age of 45, venous thromboembolism developed without an obvious cause in 38.5%, while malignant disease was identified as the most important risk factor in 23% of them. Thrombophilia was observed in 48.7% of the young women in comparison to 28.7% of the older ones (p  lt  0.0001). As for venous thromboembolism recurrence, it developed in 26.3% of young women and 17.8% of the older ones (p = 0.03). Conclusion. Younger women developed more severe forms of thrombosis than the older ones. Inherited risk factor for thrombosis was detected in almost half of all young women, and in every fourth elderly women. With the exception of factor V Leiden mutation, other types of congenital thrombophilia are almost negligible among older women. Therefore, thrombophilia testing in case of first thrombosis is fully justified only in young women.
PB  - Društvo lekara Vojvodine Srpskog lekarskog društva, Novi Sad
T2  - Medicinski pregled
T1  - Kliničke karakteristike prve venske tromboze kod mladih žena i onih starijih od 45 godina
T1  - Clinical characteristics of first venous thrombosis among women under and over 45 years of age
EP  - 333
IS  - 9-10
SP  - 328
VL  - 67
DO  - 10.2298/MPNS1410328K
ER  - 

@article{
author = "Kovač, Mirjana and Miković, Željko and Mandić, Vesna and Radojković, Dragica and Đorđević, Valentina and Mitić, Gorana",
year = "2014",
abstract = "Uvod. Venski tromboembolizam je multifaktorijalna bolest koja nastaje u interakciji genetskog i stečenog faktora rizika. Nakon bolesti koronarnih krvnih sudova i moždanog udara, najčešći je razlog kardiovaskularne smrti ili onesposobljenosti. Materijal i metode. Sa ciljem da se utvrde kliničke krakteristike prvog venskog tromboembolizma, u studiju je uključeno 447 žena mlađih od 45 i 174 žene starije od 45 godina, koje su testirane na prisustvo trombofilije u periodu 1998-2012. godine. Rezultati. Proksimalna duboka venska tromboza češće je zastupljena kod mladih žena, dok je distalna učestalija u grupi starijih. Najčešći faktor rizika za trombozu, koji je utvrđen kod 49,8% mladih žena je trudnoća i stanje posle porođaja, dok se kod 25,2% tromboza razvila bez jasno prepoznatljivog faktora rizika. U grupi starijih žena, tromboza nastaje kod 38,5% bez faktora rizika, dok je malignitet kao najznačajniji faktor rizika utvrđen kod 23%. Prisustvo trombofilije zabeleženo je kod 48,7% mladih, odnosno kod 28,7% starijih žena, p  lt  0,001. Razlika se beleži i u odnosu na ponavljane venske tromboze koje su zabeležene kod 26,3% mladih, odnosno kod 17,8% starijih žena, p = 0,03. Zaključak. Kod mladih žena se razvijaju klinički teže venske tromboze nego kod starijih. Urođeni faktor rizika otkriven je kod skoro polovine mladih ispitanica, odnosno kod svake četvrte starije žene. Sa izuzetkom faktora V Leiden mutacije ostali tipovi urođene trombofilije su gotovo zanemarljivi u grupi starijih žena. Stoga je testiranje na prisustvo trombofilije u slučaju prve tromboze, u potpunosti opravdano samo kod mlađih žena., Introduction. Venous thromboembolism is a multifactorial disease defined by multiple interactions between genetic and acquired risk factors. After coronary heart disease and stroke, venous thromboembolism is the most common cause of cardiovascular death and disability. Material and Methods. In order to investigate the clinical characteristics of first venous thromboembolism, 447 women younger than 45 and 174 over 45 years of age with confirmed venous thromboembolism, who had been tested for the presence of thrombophilia in the period 1998-2012, were included in the study. Results. Proximal deep vein thrombosis occurred most often among young women, while distal deep vein thrombosis was the most frequent in the older group. The most common reported risk for venous thromboembolism observed in 49.8% of the young women was pregnancy and puerperium, while 25.2% of them developed venous thromboembolism without any obvious cause. Among women over the age of 45, venous thromboembolism developed without an obvious cause in 38.5%, while malignant disease was identified as the most important risk factor in 23% of them. Thrombophilia was observed in 48.7% of the young women in comparison to 28.7% of the older ones (p  lt  0.0001). As for venous thromboembolism recurrence, it developed in 26.3% of young women and 17.8% of the older ones (p = 0.03). Conclusion. Younger women developed more severe forms of thrombosis than the older ones. Inherited risk factor for thrombosis was detected in almost half of all young women, and in every fourth elderly women. With the exception of factor V Leiden mutation, other types of congenital thrombophilia are almost negligible among older women. Therefore, thrombophilia testing in case of first thrombosis is fully justified only in young women.",
publisher = "Društvo lekara Vojvodine Srpskog lekarskog društva, Novi Sad",
journal = "Medicinski pregled",
title = "Kliničke karakteristike prve venske tromboze kod mladih žena i onih starijih od 45 godina, Clinical characteristics of first venous thrombosis among women under and over 45 years of age",
pages = "333-328",
number = "9-10",
volume = "67",
doi = "10.2298/MPNS1410328K"
}

Kovač, M., Miković, Ž., Mandić, V., Radojković, D., Đorđević, V.,& Mitić, G.. (2014). Kliničke karakteristike prve venske tromboze kod mladih žena i onih starijih od 45 godina. in Medicinski pregled
Društvo lekara Vojvodine Srpskog lekarskog društva, Novi Sad., 67(9-10), 328-333.
https://doi.org/10.2298/MPNS1410328K

Kovač M, Miković Ž, Mandić V, Radojković D, Đorđević V, Mitić G. Kliničke karakteristike prve venske tromboze kod mladih žena i onih starijih od 45 godina. in Medicinski pregled. 2014;67(9-10):328-333.
doi:10.2298/MPNS1410328K .

Kovač, Mirjana, Miković, Željko, Mandić, Vesna, Radojković, Dragica, Đorđević, Valentina, Mitić, Gorana, "Kliničke karakteristike prve venske tromboze kod mladih žena i onih starijih od 45 godina" in Medicinski pregled, 67, no. 9-10 (2014):328-333,
https://doi.org/10.2298/MPNS1410328K . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Miljić, Predrag
AU  - Miković, Zeljko
AU  - Mandić, Vesna
AU  - Đorđević, Valentina
AU  - Radojković, Dragica
AU  - Bereczky, Zsuzsanna
AU  - Muszbek, Laszlo
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/722
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency
EP  - 1160
IS  - 6
SP  - 1158
VL  - 133
DO  - 10.1016/j.thromres.2014.03.025
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Miljić, Predrag and Miković, Zeljko and Mandić, Vesna and Đorđević, Valentina and Radojković, Dragica and Bereczky, Zsuzsanna and Muszbek, Laszlo",
year = "2014",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency",
pages = "1160-1158",
number = "6",
volume = "133",
doi = "10.1016/j.thromres.2014.03.025"
}

Kovač, M., Mitić, G., Miljić, P., Miković, Z., Mandić, V., Đorđević, V., Radojković, D., Bereczky, Z.,& Muszbek, L.. (2014). Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 133(6), 1158-1160.
https://doi.org/10.1016/j.thromres.2014.03.025

Kovač M, Mitić G, Miljić P, Miković Z, Mandić V, Đorđević V, Radojković D, Bereczky Z, Muszbek L. Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency. in Thrombosis Research. 2014;133(6):1158-1160.
doi:10.1016/j.thromres.2014.03.025 .

Kovač, Mirjana, Mitić, Gorana, Miljić, Predrag, Miković, Zeljko, Mandić, Vesna, Đorđević, Valentina, Radojković, Dragica, Bereczky, Zsuzsanna, Muszbek, Laszlo, "Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency" in Thrombosis Research, 133, no. 6 (2014):1158-1160,
https://doi.org/10.1016/j.thromres.2014.03.025 . .

TY  - JOUR
AU  - Mitić, Gorana
AU  - Kovač, Mirjana
AU  - Jurisić, Djurdjina
AU  - Đorđević, Valentina
AU  - Ilić, Vesna
AU  - Salatić, Iva
AU  - Spasić, Dragan
AU  - Novakov-Mikić, Aleksandra
PY  - 2011
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/472
AB  - Background: Normal pregnancy is characterized by numerous changes in the hemostatic system, creating the hypercoagulable state which increases the risk of venous thromboembolic event (VTE) occurrence. The risk is further increased by the presence of inherited or acquired thrombophilia. Objective: In this study, we aimed to determine the prevalence of different types of thrombophilia in women with pregnancy-related VTE, and to investigate the possible connection between the type of thrombophilia and localization of VTE as well as the gestational age of VTE occurrence. Participants and Methods: Two hundred and two women with the first episode of pregnancy-related VTE and 130 controls were investigated. The antithrombin, protein C and protein S activity, APC resistance, FVG1691A, and FIIG20210A were determined. None of the investigated women was pregnant at the time of thrombophilia testing, and none was using oral contraceptives. Results: Thrombophilia was diagnosed in 95 patients (47%) and 7 controls (5.4%). The prevalence of FV Leiden, FIIG20210A mutations, antithrombin, PC and PS deficiencies taken together and combined thrombophilia was 22.3, 10.4, 6.9 and 6.9%, respectively. Significantly more frequent antepartum occurrence of VTE (11 vs. 3, p  lt  0.05) was found in women with natural coagulation inhibitor deficiency. Pulmonary embolism occurred more frequently in nonthrombophilic women (25 vs. 3, p  lt  0.001). Conclusion: Inherited thrombophilia was found to be considerably more frequently present in women with pregnancy- and puerperium-related VTE compared to healthy controls. Women with thrombophilia are at higher risk of developing thromboses localized in the iliacofemoral region, and women without thrombophilia are at higher risk of developing pulmonary embolism. Deficiency in natural coagulation inhibitors is associated with antepartum VTE occurrence.
PB  - Karger, Basel
T2  - Gynecologic and Obstetric Investigation
T1  - Clinical Characteristics and Type of Thrombophilia in Women with Pregnancy-Related Venous Thromboembolic Disease
EP  - 108
IS  - 2
SP  - 103
VL  - 72
DO  - 10.1159/000323828
ER  - 

@article{
author = "Mitić, Gorana and Kovač, Mirjana and Jurisić, Djurdjina and Đorđević, Valentina and Ilić, Vesna and Salatić, Iva and Spasić, Dragan and Novakov-Mikić, Aleksandra",
year = "2011",
abstract = "Background: Normal pregnancy is characterized by numerous changes in the hemostatic system, creating the hypercoagulable state which increases the risk of venous thromboembolic event (VTE) occurrence. The risk is further increased by the presence of inherited or acquired thrombophilia. Objective: In this study, we aimed to determine the prevalence of different types of thrombophilia in women with pregnancy-related VTE, and to investigate the possible connection between the type of thrombophilia and localization of VTE as well as the gestational age of VTE occurrence. Participants and Methods: Two hundred and two women with the first episode of pregnancy-related VTE and 130 controls were investigated. The antithrombin, protein C and protein S activity, APC resistance, FVG1691A, and FIIG20210A were determined. None of the investigated women was pregnant at the time of thrombophilia testing, and none was using oral contraceptives. Results: Thrombophilia was diagnosed in 95 patients (47%) and 7 controls (5.4%). The prevalence of FV Leiden, FIIG20210A mutations, antithrombin, PC and PS deficiencies taken together and combined thrombophilia was 22.3, 10.4, 6.9 and 6.9%, respectively. Significantly more frequent antepartum occurrence of VTE (11 vs. 3, p  lt  0.05) was found in women with natural coagulation inhibitor deficiency. Pulmonary embolism occurred more frequently in nonthrombophilic women (25 vs. 3, p  lt  0.001). Conclusion: Inherited thrombophilia was found to be considerably more frequently present in women with pregnancy- and puerperium-related VTE compared to healthy controls. Women with thrombophilia are at higher risk of developing thromboses localized in the iliacofemoral region, and women without thrombophilia are at higher risk of developing pulmonary embolism. Deficiency in natural coagulation inhibitors is associated with antepartum VTE occurrence.",
publisher = "Karger, Basel",
journal = "Gynecologic and Obstetric Investigation",
title = "Clinical Characteristics and Type of Thrombophilia in Women with Pregnancy-Related Venous Thromboembolic Disease",
pages = "108-103",
number = "2",
volume = "72",
doi = "10.1159/000323828"
}

Mitić, G., Kovač, M., Jurisić, D., Đorđević, V., Ilić, V., Salatić, I., Spasić, D.,& Novakov-Mikić, A.. (2011). Clinical Characteristics and Type of Thrombophilia in Women with Pregnancy-Related Venous Thromboembolic Disease. in Gynecologic and Obstetric Investigation
Karger, Basel., 72(2), 103-108.
https://doi.org/10.1159/000323828

Mitić G, Kovač M, Jurisić D, Đorđević V, Ilić V, Salatić I, Spasić D, Novakov-Mikić A. Clinical Characteristics and Type of Thrombophilia in Women with Pregnancy-Related Venous Thromboembolic Disease. in Gynecologic and Obstetric Investigation. 2011;72(2):103-108.
doi:10.1159/000323828 .

Mitić, Gorana, Kovač, Mirjana, Jurisić, Djurdjina, Đorđević, Valentina, Ilić, Vesna, Salatić, Iva, Spasić, Dragan, Novakov-Mikić, Aleksandra, "Clinical Characteristics and Type of Thrombophilia in Women with Pregnancy-Related Venous Thromboembolic Disease" in Gynecologic and Obstetric Investigation, 72, no. 2 (2011):103-108,
https://doi.org/10.1159/000323828 . .

TY  - CONF
AU  - Mitić, Gorana
AU  - Kovač, Mirjana
AU  - Povazan, Ljubica
AU  - Đorđević, Valentina
AU  - Ilić, Vesna
AU  - Salatić, Iva
AU  - Lazić, Radmila
AU  - Antonijević, Nebojša
AU  - Novakov-Mikić, Aleksandra
PY  - 2010
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/424
AB  - Introduction The optimal treatment of pregnancy associated VTE (venous thromboembolism) has not been established yet. Objective The assessment of the efficacy and safety of low molecular weight heparin (LMWH) nadroparin and unfractionated heparin (UFH) used for the treatment of pregnancy and puerperium related VTE. Primary study goals were to analyze the incidence of recurrent VTE (proximal extension or pulmonary thromboembolism), thrombocytopenia, major and minor hemorrhages and skin allergic reactions. The study also included the incidence of miscarriages, stillbirth and neonatal abnormalities. We also studied the relationship between the presence of thrombophilia and the occurrence of complications during VIE treatment. Methods Seventy-two women with antepartal VTE treated with s.c. LMWH during entire pregnancy and 88 women with postpartal VIE initially treated with either s.c. LMWH or i.v.UFH were under follow-up during the entire treatment. Thrombophilia testing included antithrombin, protein C and protein S activity levels, Activated protein C (APC) resistance, LA, ACL, FV Leiden, FII G20210A and MTHFR C677T mutations. Results Twice a day weight based therapeutic regimen was applied for LMWH and activated partial thromboplastin time (aPTT) adjusted UFH dosages. After 2-6 weeks of antepartal deep vein thrombosis (DVT) treatment the dose of nadroparin was reduced to intermediate level. The duration of LMWH therapy during pregnancy was 1-35 weeks, on average 16 weeks. One case (0.62%) of DVT propagation into the vena cava occurred in a woman with antithrombin deficiency treated with LMWH. Two women (1.25%) had minor bleeding and 5 (3.125%) had minimal bleeding, while 3 (1.9%) had skin allergic reactions. The rate of successful pregnancy outcome was 97.2%. There were no cases of stillbirth or neonatal congenital abnormalities. Thrombophilia was found in 86 women (53.7%). No statistically significant correlation between the presence of thrombophilia and treatment complications were found. Conclusion Nadroparin is both safe and effective for the treatment of DVT during pregnancy and puerperium.
PB  - Srpsko lekarsko društvo, Beograd
C3  - Srpski arhiv za celokupno lekarstvo
T1  - Efficacy and Safety of Nadroparin and Unfractionated Heparin for the Treatment of Venous Thromboembolism During Pregnancy and Puerperium
EP  - 22
SP  - 18
VL  - 138
DO  - 10.2298/SARH10S1018M
ER  - 

@conference{
author = "Mitić, Gorana and Kovač, Mirjana and Povazan, Ljubica and Đorđević, Valentina and Ilić, Vesna and Salatić, Iva and Lazić, Radmila and Antonijević, Nebojša and Novakov-Mikić, Aleksandra",
year = "2010",
abstract = "Introduction The optimal treatment of pregnancy associated VTE (venous thromboembolism) has not been established yet. Objective The assessment of the efficacy and safety of low molecular weight heparin (LMWH) nadroparin and unfractionated heparin (UFH) used for the treatment of pregnancy and puerperium related VTE. Primary study goals were to analyze the incidence of recurrent VTE (proximal extension or pulmonary thromboembolism), thrombocytopenia, major and minor hemorrhages and skin allergic reactions. The study also included the incidence of miscarriages, stillbirth and neonatal abnormalities. We also studied the relationship between the presence of thrombophilia and the occurrence of complications during VIE treatment. Methods Seventy-two women with antepartal VTE treated with s.c. LMWH during entire pregnancy and 88 women with postpartal VIE initially treated with either s.c. LMWH or i.v.UFH were under follow-up during the entire treatment. Thrombophilia testing included antithrombin, protein C and protein S activity levels, Activated protein C (APC) resistance, LA, ACL, FV Leiden, FII G20210A and MTHFR C677T mutations. Results Twice a day weight based therapeutic regimen was applied for LMWH and activated partial thromboplastin time (aPTT) adjusted UFH dosages. After 2-6 weeks of antepartal deep vein thrombosis (DVT) treatment the dose of nadroparin was reduced to intermediate level. The duration of LMWH therapy during pregnancy was 1-35 weeks, on average 16 weeks. One case (0.62%) of DVT propagation into the vena cava occurred in a woman with antithrombin deficiency treated with LMWH. Two women (1.25%) had minor bleeding and 5 (3.125%) had minimal bleeding, while 3 (1.9%) had skin allergic reactions. The rate of successful pregnancy outcome was 97.2%. There were no cases of stillbirth or neonatal congenital abnormalities. Thrombophilia was found in 86 women (53.7%). No statistically significant correlation between the presence of thrombophilia and treatment complications were found. Conclusion Nadroparin is both safe and effective for the treatment of DVT during pregnancy and puerperium.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Efficacy and Safety of Nadroparin and Unfractionated Heparin for the Treatment of Venous Thromboembolism During Pregnancy and Puerperium",
pages = "22-18",
volume = "138",
doi = "10.2298/SARH10S1018M"
}

Mitić, G., Kovač, M., Povazan, L., Đorđević, V., Ilić, V., Salatić, I., Lazić, R., Antonijević, N.,& Novakov-Mikić, A.. (2010). Efficacy and Safety of Nadroparin and Unfractionated Heparin for the Treatment of Venous Thromboembolism During Pregnancy and Puerperium. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 138, 18-22.
https://doi.org/10.2298/SARH10S1018M

Mitić G, Kovač M, Povazan L, Đorđević V, Ilić V, Salatić I, Lazić R, Antonijević N, Novakov-Mikić A. Efficacy and Safety of Nadroparin and Unfractionated Heparin for the Treatment of Venous Thromboembolism During Pregnancy and Puerperium. in Srpski arhiv za celokupno lekarstvo. 2010;138:18-22.
doi:10.2298/SARH10S1018M .

Mitić, Gorana, Kovač, Mirjana, Povazan, Ljubica, Đorđević, Valentina, Ilić, Vesna, Salatić, Iva, Lazić, Radmila, Antonijević, Nebojša, Novakov-Mikić, Aleksandra, "Efficacy and Safety of Nadroparin and Unfractionated Heparin for the Treatment of Venous Thromboembolism During Pregnancy and Puerperium" in Srpski arhiv za celokupno lekarstvo, 138 (2010):18-22,
https://doi.org/10.2298/SARH10S1018M . .

TY  - JOUR
AU  - Mitić, Gorana
AU  - Kovač, Mirjana
AU  - Povazan, Ljubica
AU  - Magić, Zvonko
AU  - Đorđević, Valentina
AU  - Salatić, Iva
AU  - Mitić, Igor
AU  - Novakov-Mikić, Aleksandra
PY  - 2010
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/461
AB  - Recurrent fetal loss (RFL) is a significant clinical problem, occurring in 1% to 5% of reproductive females. Inherited or acquired thrombophilia has been diagnosed in 50% to 65% of women with history of unexplained fetal loss. The objective of our study was to determine the prevalence of thrombophilia in women with unexplained RFL in Serbian population and to find out whether the presence of thrombophilia is associated with pregnancy losses that occur later than 12th gestational week. We have examined 147 women with unexplained RFL or intrauterine fetal death and 128 healthy women with at least 1 uncomplicated pregnancy. The antithrombin (AT), protein C (PC), protein S (PS), activated protein C (APC) resistance, factor V (FV) G1691A, factor II (FII) G20210A, and MTHFR C677T were determined. At least 1 inherited thrombophilic defect was found in 54 (36.7%) of 147 women with repeated fetal losses and in 11 (8.59%) of 128 controls (P  lt  .001, OR 6.17, 95% CI 3.06-12.48). The most common thrombophilic abnormalities were homozygosity for MTHFR 677TT, FV Leiden, and FII G20210A. Deficiency of natural anticoagulants occurred in 10 patients, with protein S deficiency being the most frequent one. Thrombophilia was found in 46 of 94 women with RFL that occurred later than the 12th gestational week and in only 8 of 53 with RPL earlier than 12th week (P = .001). Our study has shown the association between the hereditary thrombophilia and RFL that occurred after the 12th gestational week in Serbian population.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Clinical and Applied Thrombosis-Hemostasis
T1  - Inherited Thrombophilia is Associated With Pregnancy Losses That Occur After 12th Gestational Week in Serbian Population
EP  - 439
IS  - 4
SP  - 435
VL  - 16
DO  - 10.1177/1076029609335518
ER  - 

@article{
author = "Mitić, Gorana and Kovač, Mirjana and Povazan, Ljubica and Magić, Zvonko and Đorđević, Valentina and Salatić, Iva and Mitić, Igor and Novakov-Mikić, Aleksandra",
year = "2010",
abstract = "Recurrent fetal loss (RFL) is a significant clinical problem, occurring in 1% to 5% of reproductive females. Inherited or acquired thrombophilia has been diagnosed in 50% to 65% of women with history of unexplained fetal loss. The objective of our study was to determine the prevalence of thrombophilia in women with unexplained RFL in Serbian population and to find out whether the presence of thrombophilia is associated with pregnancy losses that occur later than 12th gestational week. We have examined 147 women with unexplained RFL or intrauterine fetal death and 128 healthy women with at least 1 uncomplicated pregnancy. The antithrombin (AT), protein C (PC), protein S (PS), activated protein C (APC) resistance, factor V (FV) G1691A, factor II (FII) G20210A, and MTHFR C677T were determined. At least 1 inherited thrombophilic defect was found in 54 (36.7%) of 147 women with repeated fetal losses and in 11 (8.59%) of 128 controls (P  lt  .001, OR 6.17, 95% CI 3.06-12.48). The most common thrombophilic abnormalities were homozygosity for MTHFR 677TT, FV Leiden, and FII G20210A. Deficiency of natural anticoagulants occurred in 10 patients, with protein S deficiency being the most frequent one. Thrombophilia was found in 46 of 94 women with RFL that occurred later than the 12th gestational week and in only 8 of 53 with RPL earlier than 12th week (P = .001). Our study has shown the association between the hereditary thrombophilia and RFL that occurred after the 12th gestational week in Serbian population.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Clinical and Applied Thrombosis-Hemostasis",
title = "Inherited Thrombophilia is Associated With Pregnancy Losses That Occur After 12th Gestational Week in Serbian Population",
pages = "439-435",
number = "4",
volume = "16",
doi = "10.1177/1076029609335518"
}

Mitić, G., Kovač, M., Povazan, L., Magić, Z., Đorđević, V., Salatić, I., Mitić, I.,& Novakov-Mikić, A.. (2010). Inherited Thrombophilia is Associated With Pregnancy Losses That Occur After 12th Gestational Week in Serbian Population. in Clinical and Applied Thrombosis-Hemostasis
Sage Publications Inc, Thousand Oaks., 16(4), 435-439.
https://doi.org/10.1177/1076029609335518

Mitić G, Kovač M, Povazan L, Magić Z, Đorđević V, Salatić I, Mitić I, Novakov-Mikić A. Inherited Thrombophilia is Associated With Pregnancy Losses That Occur After 12th Gestational Week in Serbian Population. in Clinical and Applied Thrombosis-Hemostasis. 2010;16(4):435-439.
doi:10.1177/1076029609335518 .

Mitić, Gorana, Kovač, Mirjana, Povazan, Ljubica, Magić, Zvonko, Đorđević, Valentina, Salatić, Iva, Mitić, Igor, Novakov-Mikić, Aleksandra, "Inherited Thrombophilia is Associated With Pregnancy Losses That Occur After 12th Gestational Week in Serbian Population" in Clinical and Applied Thrombosis-Hemostasis, 16, no. 4 (2010):435-439,
https://doi.org/10.1177/1076029609335518 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Miković, Zeljko
AU  - Antonijević, Nebojša
AU  - Đorđević, Valentina
AU  - Miković, Danijela
AU  - Mandić, Vesna
AU  - Rakićević, Ljiljana
AU  - Radojković, Dragica
PY  - 2010
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/412
AB  - Factor V Leiden (FVLeiden) and prothrombin G20210A are the most common genetic causes of thrombophilia and established risk factors for different clinical manifestations of venous thromboembolism (VTE). This study investigated whether the clinical manifestation of VTE, the extension of deep vein thrombosis (DVT) and the presence of transient risk factors at the time of the first VTE, differed among patients with mutations (97 with FVLeiden; 33 with prothrombin G20210A) and in 109 patients without thrombophilia. Isolated pulmonary embolism (PE) was less prevalent in patients with FVLeiden (6%) and no thrombophilia (6%) than in those with prothrombin G20210A (15%). No difference was found in the incidence of distal DVT. Regarding the extension of proximal DVT, the lowest incidence for isolated popliteal vein and the highest for iliofemoral vein were observed in patients with prothrombin G20210A. No difference was observed between groups of patients with or without thrombophilia by unprovoked VTE. The pregnancy/puerperium was the most prevalent risk factor in carriers of prothrombin G20210A. Among FVLeiden carriers, the most prevalent risk factor was surgery, and in patients without thrombophilia, it was trauma (P  lt  .05). Thrombosis of the upper limb was more frequent in a group without thrombophilia than in patients with mutations (P  lt  .01). Transverse sinus venous thrombosis was present only in patients with prothrombin G20210A. Carriers of prothrombin G20210A have an increased risk of developing isolated PE and more severe clinical manifestations than those with FVLeiden or without thrombophilia.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Clinical and Applied Thrombosis-Hemostasis
T1  - Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation
EP  - 70
IS  - 1
SP  - 66
VL  - 16
DO  - 10.1177/1076029608320721
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Miković, Zeljko and Antonijević, Nebojša and Đorđević, Valentina and Miković, Danijela and Mandić, Vesna and Rakićević, Ljiljana and Radojković, Dragica",
year = "2010",
abstract = "Factor V Leiden (FVLeiden) and prothrombin G20210A are the most common genetic causes of thrombophilia and established risk factors for different clinical manifestations of venous thromboembolism (VTE). This study investigated whether the clinical manifestation of VTE, the extension of deep vein thrombosis (DVT) and the presence of transient risk factors at the time of the first VTE, differed among patients with mutations (97 with FVLeiden; 33 with prothrombin G20210A) and in 109 patients without thrombophilia. Isolated pulmonary embolism (PE) was less prevalent in patients with FVLeiden (6%) and no thrombophilia (6%) than in those with prothrombin G20210A (15%). No difference was found in the incidence of distal DVT. Regarding the extension of proximal DVT, the lowest incidence for isolated popliteal vein and the highest for iliofemoral vein were observed in patients with prothrombin G20210A. No difference was observed between groups of patients with or without thrombophilia by unprovoked VTE. The pregnancy/puerperium was the most prevalent risk factor in carriers of prothrombin G20210A. Among FVLeiden carriers, the most prevalent risk factor was surgery, and in patients without thrombophilia, it was trauma (P  lt  .05). Thrombosis of the upper limb was more frequent in a group without thrombophilia than in patients with mutations (P  lt  .01). Transverse sinus venous thrombosis was present only in patients with prothrombin G20210A. Carriers of prothrombin G20210A have an increased risk of developing isolated PE and more severe clinical manifestations than those with FVLeiden or without thrombophilia.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Clinical and Applied Thrombosis-Hemostasis",
title = "Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation",
pages = "70-66",
number = "1",
volume = "16",
doi = "10.1177/1076029608320721"
}

Kovač, M., Mitić, G., Miković, Z., Antonijević, N., Đorđević, V., Miković, D., Mandić, V., Rakićević, L.,& Radojković, D.. (2010). Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation. in Clinical and Applied Thrombosis-Hemostasis
Sage Publications Inc, Thousand Oaks., 16(1), 66-70.
https://doi.org/10.1177/1076029608320721

Kovač M, Mitić G, Miković Z, Antonijević N, Đorđević V, Miković D, Mandić V, Rakićević L, Radojković D. Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation. in Clinical and Applied Thrombosis-Hemostasis. 2010;16(1):66-70.
doi:10.1177/1076029608320721 .

Kovač, Mirjana, Mitić, Gorana, Miković, Zeljko, Antonijević, Nebojša, Đorđević, Valentina, Miković, Danijela, Mandić, Vesna, Rakićević, Ljiljana, Radojković, Dragica, "Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation" in Clinical and Applied Thrombosis-Hemostasis, 16, no. 1 (2010):66-70,
https://doi.org/10.1177/1076029608320721 . .